The estimated Net Worth of Albert Seymour is at least $3.67 Million dollars as of 6 September 2023. Mr. Seymour owns over 4,620 units of Homology Medicines Inc stock worth over $141,659 and over the last 7 years he sold FIXX stock worth over $1,647,082. In addition, he makes $1,876,830 as Chief Scientific Officer at Homology Medicines Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Seymour FIXX stock SEC Form 4 insiders trading
Albert has made over 13 trades of the Homology Medicines Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 4,620 units of FIXX stock worth $4,297 on 6 September 2023.
The largest trade he's ever made was selling 18,600 units of Homology Medicines Inc stock on 29 November 2019 worth over $300,390. On average, Albert trades about 6,149 units every 78 days since 2018. As of 6 September 2023 he still owns at least 152,322 units of Homology Medicines Inc stock.
You can see the complete history of Mr. Seymour stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Albert Seymour biography
Albert Seymour Ph.D. serves as Chief Scientific Officer of the Company. Prior to joining Homology, Dr. Seymour was Senior Vice President, Head of Global Research and Nonclinical Development at Shire plc, a biotechnology company, from 2011 to 2016. Dr. Seymour received his B.A. in Biology from the University of Delaware, an M.S. from Johns Hopkins University School of Medicine and his Ph.D. in Human Genetics from the University of Pittsburgh.
What is the salary of Albert Seymour?
As the Chief Scientific Officer of Homology Medicines Inc, the total compensation of Albert Seymour at Homology Medicines Inc is $1,876,830. There are 2 executives at Homology Medicines Inc getting paid more, with Arthur Tzianabos having the highest compensation of $5,062,880.
How old is Albert Seymour?
Albert Seymour is 52, he's been the Chief Scientific Officer of Homology Medicines Inc since 2016. There are 12 older and 4 younger executives at Homology Medicines Inc. The oldest executive at Homology Medicines Inc is Steven Gillis, 67, who is the Independent Director.
What's Albert Seymour's mailing address?
Albert's mailing address filed with the SEC is C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD, MA, 01730.
Insiders trading at Homology Medicines Inc
Over the last 7 years, insiders at Homology Medicines Inc have traded over $108,214,465 worth of Homology Medicines Inc stock and bought 3,033,333 units worth $51,999,993 . The most active insiders traders include Steven Gillis, James Edeerfield Management..., and Kush Parmar. On average, Homology Medicines Inc executives and independent directors trade stock every 26 days with the average trade being worth of $106,785. The most recent stock trade was executed by Paul Alloway on 25 March 2024, trading 23,530 units of FIXX stock currently worth $21,883.
What does Homology Medicines Inc do?
homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
What does Homology Medicines Inc's logo look like?
Complete history of Mr. Seymour stock trades at Homology Medicines Inc
Homology Medicines Inc executives and stock owners
Homology Medicines Inc executives and other stock owners filed with the SEC include:
-
Arthur Tzianabos,
President, Chief Executive Officer, Director -
Tim Kelly,
Chief Technical Operations Officer -
Albert Seymour,
Chief Scientific Officer -
W. Bradford Smith,
Chief Financial Officer, Treasurer and Secretary -
Dr. Arthur O. Tzianabos Ph.D.,
Pres, CEO & Director -
Dr. Albert Seymour Ph.D.,
Chief Scientific Officer -
W. Bradford Smith CPA, M.B.A.,
CFO & Treasurer -
Alise Reicin,
Independent Director -
Kush Parmar,
Independent Director -
Mary Thistle,
Independent Director -
Richard Gregory,
Independent Director -
Matthew Patterson,
Independent Director -
Steven Gillis,
Independent Director -
Jeffrey Poulton,
Director -
Gabriel Cohn,
Chief Medical Officer -
Cara Mayfield,
Director of Corp. Communications -
Dr. Deborah Kinch Ph.D.,
Chief Devel. Officer -
Dr. Julie Jordan M.D.,
Sr. VP and Head of Clinical Devel. & Operations -
Michael Blum M.B.A.,
Chief Commercial Officer -
Dr. Gabriel M. Cohn M.B.A., M.D.,
Chief Medical Officer -
Melissa Gelormini,
VP of HR -
Theresa McNeely,
Chief Communications Officer & Patient Advocate -
Dr. Paul Alloway J.D., Ph.D.,
Chief Legal Officer & Sec. -
Timothy P. Kelly M.B.A.,
Chief Operating Officer -
Dr. Saswati Chatterjee Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Ventures Iv, L.P.5 Am Co In...,
-
Ventures Iv, L.P.5 Am Partn...,
-
Institutes For Bio Medical ...,
-
Ventures, Llcvv Manager Llc...,
-
Holdings (Private) Ltd Full...,
-
Cameron Wheeler,
Director -
Siyamak Rasty,
Chief Operating Officer -
James Edeerfield Management...,
-
James Edeerfield Management...,
-
Venture Fund Viii, L.P.Arch...,
-
Springs Capital Management ...,
-
Venture Fund Viii, L.P.Arch...,
-
Charles Jr Michaud,
See Remarks -
Paul Alloway,
See Remarks -
Michael Lee Blum,
Chief Commercial Officer -
Julie Jordan,
Chief Medical Officer